Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

Blood
Eugenio MorelliPierfrancesco Tassone

Abstract

The microRNA (miRNA) cluster miR-17-92 is oncogenic and represents a valuable therapeutic target in c-MYC (MYC)-driven malignancies. Here, we developed novel LNA gapmeR antisense oligonucleotides (ASOs) to induce ribonuclease H-mediated degradation of MIR17HG primary transcripts and consequently prevent biogenesis of miR-17-92 miRNAs (miR-17-92s). The leading LNA ASO, MIR17PTi, impaired proliferation of several cancer cell lines (n = 48) established from both solid and hematologic tumors by on-target antisense activity, more effectively as compared with miR-17-92 inhibitors. By focusing on multiple myeloma (MM), we found that MIR17PTi triggers apoptosis via impairment of homeostatic MYC/miR-17-92 feed-forward loops (FFLs) in patient-derived MM cells and induces MYC-dependent synthetic lethality. We show that alteration of a BIM-centered FFL is instrumental for MIR17PTi to induce cytotoxicity in MM cells. MIR17PTi exerts strong in vivo antitumor activity in nonobese diabetic severe combined immunodeficient mice bearing clinically relevant models of MM, with advantageous safety and pharmacokinetic profiles in nonhuman primates. Altogether, MIR17PTi is a novel pharmacological tool to be tested in early-phase clinical trials agains...Continue Reading

References

Nov 11, 1999·Current Biology : CB·M SchuhmacherF Kohlhuber
Aug 9, 2002·RNA·Yan Zeng, Bryan R Cullen
Jun 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Zirong LiBing Ren
Apr 14, 2004·Proceedings of the National Academy of Sciences of the United States of America·Alexander EgleSuzanne Cory
Apr 9, 2005·Blood·Pierfrancesco TassoneNikhil C Munshi
Jun 10, 2005·Nature·Lin HeScott M Hammond
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Nov 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Karen I ZellerChia-Lin Wei
Jun 15, 2007·Molecular Cell·John TsangAlexander van Oudenaarden
Mar 11, 2009·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Natalia J Martinez, Albertha J M Walhout
Dec 17, 2009·Genes & Development·Virginie OliveLin He
Mar 21, 2012·The Journal of Experimental Medicine·Dai HoriuchiAndrei Goga
Jun 1, 2012·The Cancer Journal·Carla P ConcepcionAndrea Ventura
Jan 19, 2013·Nature Reviews. Genetics·Stephane E Castel, Robert A Martienssen
Mar 22, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nikhil C Munshi, Kenneth C Anderson
Apr 5, 2013·Immunological Reviews·Virginie OliveLin He
Jan 17, 2014·Nature Communications·Niccolo BolliNikhil C Munshi
Sep 2, 2014·Cell Reports·Nathiya MuthalaguDaniel J Murphy
Feb 11, 2015·Advanced Drug Delivery Reviews·Richard S GearyC Frank Bennett
Oct 16, 2015·Cancer Cell·Zachary E Stine, Chi V Dang
Nov 12, 2015·Nature Communications·Marija MihailovichTiziana Bonaldi
Jan 16, 2016·Cell Systems·Arthur LiberzonPablo Tamayo
Apr 9, 2016·Journal of Basic and Clinical Pharmacy·Anroop B Nair, Shery Jacob
Jun 22, 2016·Molecular Therapy. Nucleic Acids·Maria Eugenia Gallo CantafioMaria Teresa Di Martino
Feb 9, 2017·Cold Spring Harbor Symposia on Quantitative Biology·Chi V Dang
Apr 6, 2017·The New England Journal of Medicine·Michel AttalUNKNOWN IFM 2009 Study

❮ Previous
Next ❯

Citations

Aug 28, 2018·Expert Review of Hematology·Daniele CaraccioloPierfrancesco Tassone
Jan 19, 2019·Non-coding RNA·Irena Misiewicz-KrzeminskaNorma C Gutiérrez
Mar 16, 2019·Immunological Reviews·Julia MaulDirk Baumjohann
May 6, 2019·Non-coding RNA·Cinzia FedericoAldo M Roccaro
Jan 7, 2020·Chinese Medical Journal·Fei-Yan WangChun-Ji Gao
Feb 6, 2020·Cancers·Eugenio MorelliNicola Amodio
Sep 8, 2018·Blood·Lawrence H Boise
May 12, 2019·International Journal of Molecular Sciences·Beomku KangBonglee Kim
Mar 6, 2019·International Journal of Molecular Sciences·Frank HillebrandHeiner Schaal
Oct 9, 2019·Cell Death and Differentiation·Kerstin BrinkmannMarco J Herold
Mar 23, 2019·Journal of Hematology & Oncology·Maria CucèCirino Botta
Oct 18, 2020·International Journal of Molecular Sciences·Amro M SolimanSrijit Das
Jul 25, 2020·Haematologica·Annamaria Gulla, Kenneth C Anderson
Oct 16, 2020·Haematologica·Annamaria Gulla, Kenneth C Anderson
Apr 4, 2021·Cancers·Maria Teresa Di MartinoPierfrancesco Tassone
May 4, 2021·Journal of Leukocyte Biology·Yishan YeHe Huang
Jul 27, 2021·Cancer Science·Sho Ikeda, Hiroyuki Tagawa
Sep 11, 2021·Cancers·Daniele CaraccioloPierfrancesco Tassone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.